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Amyloid beta selectively modulates neuronal TrkB alternative transcript 
expression with implications for Alzheimer's disease 
Abstract 
Dysregulation in brain-derived neurotrophic factor (BDNF)/full-length TrkB (TrkB-TK+) signaling is 
implicated in promoting neurodegeneration in Alzheimer's disease (AD). BDNF/TrkB-TK+ signaling can be 
modulated by the presence of truncated TrkB isoforms (TrkB-TK-, TrkB-Shc). All TrkB isoforms are 
encoded by different alternative transcripts. In this study, we assessed if expression of the three main 
TrkB alternative transcripts, TrkB-TK+, TrkB-TK-, and TrkB-Shc are altered in AD. Using a cohort of control 
and AD brains (n=29), we surveyed the hippocampus, temporal cortex, occipital cortex, and cerebellum 
and found specific increases in TrkB-Shc, a neuron-specific transcript, in the AD hippocampus. No 
significant changes were detected in TrkB-TK+ and TrkB-TK- transcript levels in AD in any brain region 
examined. Corresponding changes in truncated TrkB protein levels were found in the hippocampus, 
although a significant increase in the temporal cortex was also observed. Our findings suggested that 
neuron-specific changes in TrkB may be occurring in AD; thus, we determined whether TrkB-Shc 
expression could be modulated by amyloid beta 1-42 (Aβ 42). We found increased TrkB-Shc mRNA levels 
in differentiated SHSY5Y neuronal cell-lines exposed to fibril-containing Aβ 42 preparations. When we 
assessed the cellular impact of increased TrkB-Shc, we found co-localization between TrkB-Shc and TrkB-
TK+. Interestingly, TrkB-Shc overexpression selectively attenuated BDNF/TrkB-TK+-mediated signaling via 
the mitogen-activated protein kinase kinase (MEK) pathway, but not the protein kinase B pathway. In AD, 
MEK signaling is increased in vulnerable neurons and linked to abnormal phosphorylation of cytoskeletal 
proteins. Altogether, our findings suggest that elevated TrkB-Shc expression in AD may function as a 
compensatory response in neurons in AD to promote survival. 
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Abstract
Dysregulation in brain-derived neurotrophic factor (BDNF)/full-lengthTrkB (TrkB-TK+) 
signaling is implicated in promoting neurodegeneration in Alzheimer’s Disease (AD). 
BDNF/TrkB-TK+ signaling can be modulated by the presence of truncated TrkB isoforms 
(TrkB-TK-, TrkB-Shc). All TrkB isoforms are encoded by different alternative transcripts. In 
this study, we assessed if expression of the three main TrkB alternative transcripts, TrkB-
TK+, TrkB-TK-, and TrkB-Shc are altered in AD. Using a cohort of control and AD brains 
(n=29), we surveyed the hippocampus, temporal cortex, occipital cortex, and cerebellum and 
found specific increases in TrkB-Shc, a neuron-specific transcript, in the AD hippocampus. 
No significant changes were detected in TrkB-TK+ and TrkB-TK- transcript levels in AD in 
any brain region examined. Corresponding changes in truncated TrkB protein levels were 
found in the hippocampus although a significant increase in the temporal cortex was also 
observed. Our findings suggested that neuron-specific changes in TrkB may be occurring in 
AD, thus we determined whether TrkB-Shc expression could be modulated by amyloid beta 
1-42 (A). We found increased TrkB-Shc mRNA levels in differentiated SHSY5Y neuronal 
cell-lines exposed to fibril-containing Apreparations. When we assessed the cellular 
impact of increased TrkB-Shc, we found co-localization between TrkB-Shc and TrkB-TK+. 
Interestingly, TrkB-Shc overexpression selectively attenuated BDNF/TrkB-TK+-mediated 
signaling via the MEK pathway but not the AKT pathway. In AD, MEK signaling is 
increased in vulnerable neurons and linked to abnormal phosphorylation of cytoskeletal 
proteins. Altogether, our findings suggest that elevated TrkB-Shc expression in AD may 
function as a compensatory response in neurons in AD to promote survival. 
 
Key Words:  TrkB, BDNF, amyloid, neurotrophin, neurodegeneration, hippocampus 
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Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative diseases in humans 
and is characterized by amyloid- (A) deposition, tau neurofibrillary tangles, and neuronal 
loss. Deficits in brain-derived neurotrophic factor (BDNF) signaling have been proposed to 
facilitate the progressive neurodegeneration in AD (Schindowski et al., 2008). The growth 
promoting actions of BDNF are critical for survival and plasticity of a variety of neurons 
throughout the brain. Moreover, BDNF has been demonstrated to be vital for neuronal 
growth, differentiation, axonal guidance, behavior, cognition and memory formation; and 
hippocampal neurogenesis (Knusel et al., 1991, Ghosh et al., 1994, McAllister et al., 1995, 
Itami et al., 2000, Mizuno et al., 2000, Alonso et al., 2002, Lu et al., 2008, Schindowski et al., 
2008, Gao and Chen, 2009, Gao et al., 2009). The neurotrophic effects of BDNF are 
mediated by the tropomyosin receptor kinase B (TrkB), a membrane-bound receptor tyrosine 
kinase which can activate various cell signaling pathways linked to growth, differentiation, 
and survival (Patapoutian and Reichardt, 2001, Bartkowska et al., 2010).   
The TrkB gene is expressed as multiple alternative splice transcripts that give rise to 
different protein isoforms (Luberg et al., 2010). Three major TrkB transcripts/isoforms are 
expressed in the human brain (Stoilov et al., 2002, Luberg et al., 2010). The high affinity, 
full-length (TrkB-TK+) TrkB receptor is encoded by 24 exons and is expressed primarily by 
neurons. It contains a catalytic tyrosine kinase domain that is necessary for activating second 
messenger signaling via the MEK, AKT, and PLC pathways to mediate the neurotrophic 
effects of BDNF (Klein et al., 1991, Stoilov et al., 2002, Luberg et al., 2010) (Fig. 1). The C-
terminal truncated TrkB receptors include TrkB-TK- and TrkB-Shc. TrkB-TK- is encoded by 
16 exons and is expressed primarily by glia, although expression in neurons has also been 
reported (Stoilov et al., 2002, Ohira and Hayashi, 2003, Ohira et al., 2005a, Ohira et al., 
2005b, Luberg et al., 2010). Unlike TrkB-TK+ transcripts which do not have exon 16, TrkB-
TK- transcripts include exon 16. Exon 16 encodes a stop codon and this leads to the 
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generation of a short isoform-specific C-terminal domain that lacks the catalytic tyrosine 
kinase domain (Klein et al., 1990) (Fig. 1). Thus, TrkB-TK- may inhibit neurotrophin 
signaling by sequestering or trapping neurotrophins to prevent binding and signal 
transduction via TrkB-TK+ homodimers (Biffo et al., 1995, Fryer et al., 1997), or act in a 
manner similar to “antigen presenting” receptors by binding to BDNF and presenting it to 
nearby cells expressing TrkB-TK+ (Beck et al., 1993, Frisen et al., 1993). Alternatively, 
TrkB-TK- has been demonstrated in vitro to act as a dominant-negative receptor when co-
expressed in the same cell type by forming inactive heterodimers with TrkB-TK+ to prevent 
neurotrophin signaling (Eide et al., 1996, Ninkina et al., 1996). The other major C-terminal 
truncated TrkB receptor isoform, TrkB-Shc, differs from TrkB-TK- in that it is expressed 
only by neurons (Stoilov et al., 2002). It contains a sarc homology binding site (Shc) in the 
juxtamembrane domain similar to TrkB-TK+, however, TrkB-Shc transcripts include exon 19 
which is not present in TrkB-TK+ transcripts. Exon 19 also contains a stop codon that leads 
to the translation of a unique truncated C-terminus which also lacks the tyrosine kinase 
domain (Stoilov et al., 2002) (Fig. 1). Thus, TrkB-Shc may also act as a negative regulator of 
TrkB-TK+ as it is able to dimerize with TrkB-TK+ but is unable to signal via tyrosine kinase 
(Stoilov et al., 2002).  
At present, studies examining changes in TrkB mRNA and protein expression in AD 
are incomplete and conflicting changes in TrkB-TK+ and TrkB-TK- expression have been 
reported. In AD brains, reductions in TrkB-TK+ protein in neurons have mostly been found 
in the hippocampus and the temporal and frontal cortices (Allen et al., 1999, Ferrer et al., 
1999). Others have reported no loss of TrkB immunnoreactivity in AD parietal cortex, 
however this was using an antibody to TrkB-TK- (Savaskan et al., 2000). Moreover, previous 
studies of TrkB expression in the hippocampus of AD brains have only examined TrkB-TK+ 
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and TrkB-TK- protein expression by immunohistochemistry and western blotting (Connor et 
al., 1996, Ferrer et al., 1999). 
Interestingly, while the existence of TrkB-Shc has been known for some time, its role 
in AD has yet to be described. Considering that TrkB-Shc has been characterized to be 
expressed only in neurons (Stoilov et al., 2002), and that neurotrophin signaling is decreased 
in neurons in AD, it is important to establish what role TrkB-Shc plays in AD development 
and progression. 
In the present study, we took a quantitative approach to specifically measure the 
expression levels of each of the three major TrkB alternative splice variants (TrkB-TK+, 
TrkB-TK-, and TrkB-Shc) in the hippocampus (a region heavily impacted in AD), temporal 
cortex (a region also affected in AD), occipital cortex (an area affected late in AD), and 
cerebellum (a region relatively spared in AD) of AD brains. Considering that TrkB-Shc is 
neuronal specific, we also determined if changes in its expression could be modulated in an 
amyloidogenic environment and whether increased TrkB-Shc has a functional impact on 
BDNF/TrkB-TK+ signaling in a neuronal setting.  
 




Two brain cohorts were used in this study. For the hippocampus and cerebellum, the brain 
cohort comprised n=6 controls and n=6 AD cases (Sydney Brain Bank and New South Wales 
Tissue Resource Centre, Sydney, Australia). For the temporal and occipital cortices, the brain 
cohort comprised n=8 controls and n=9 AD cases (this was generously provided by Professor 
Glenda Halliday). All cases were longitudinally evaluated to autopsy, and data and brain 
collected for research purposes as approved by Institutional Human Ethics Committees. AD 
brains were clinically and pathologically defined using NIA-Reagan criteria as described 
previously (NIA, 1997, Gregory et al., 2006, Kim et al., 2010). All AD cases had Braak 
neuritic stages V and VI. Demographic data for the cohorts are detailed in Table 1. Control 
and AD cases were matched for age and gender where possible. The diagnostic groups did 
not differ according to age, brain pH, or postmortem interval (PMI) (all p0.12).  Samples 
were taken from the same anatomical regions of the brain, as previously described (Kim et 
al., 2010)
Cell culture and treatments 
SHSY5Y cells were obtained from the American Type Culture Collection (ATCC) and 
grown at 37°C in a 5% CO2 atmosphere. For continuous culture, SHSY5Y cells were 
cultured in RPMI media containing 10% (v/v) FBS supplemented with glutamax (2 mM).  
For experiments, SHSY5Y cells were differentiated for 9 days using all-trans retinoic acid 
(ATRA:10 M) which was added to the culture medium. During differentiation, the 
differentiation media (growth media + ATRA) was refreshed every 3 days. For transfections, 
differentiated SHSY5Y cells were transfected using OptiMEM medium and Lipofectamine 
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2000 (Invitrogen). For treatments, serum-free RPMI media supplemented with N2 was used. 
Cells were treated with BDNF for 15 min prior to harvest. For A42 experiments, cells were 
treated for 6 h and harvested. No cell-toxicity was observed in any of the treatment conditions 
at the concentration employed. 
 
RNA extraction, cDNA synthesis, and quantitative real-time PCR (qPCR) 
Total RNA was extracted from tissues (20 mg) and cells using Trizol Reagent according to 
the manufacturer’s instructions (Invitrogen). Concentrations of total RNA were measured 
using a Nanodrop 2000c Spectrophotometer (ThermoScientific).  Reverse Transcriptase-PCR 
was performed according to the manufacturer’s protocol for the SuperScript III First Strand 
cDNA Synthesis Kit (Invitrogen). QPCR was performed using Sso Fast Evagreen Supermix 
(BioRad) on a Roche LightCycler 480 with a 96-well format (Roche). Primer pairs used for 
gene expression analyses are listed in Table 2.  Primers were designed to span an intron/exon 
boundary to avoid amplification of possible genomic DNA. PCR cycling conditions were: 
95°C for 1 min, 45 cycles of 95°C for 30 seconds, primer specific annealing temperature for 
30 seconds (Table 2), and 72°C for 30 seconds. Control reactions with no template were 
included which produced no signal. Melt curve analysis and agarose gel electrophoresis were 
performed to confirm production of a single product. Changes in gene expression levels were 
determined by normalizing mRNA levels of the gene of interest to the mRNA level of the 
housekeeping gene, -actin using the 2-CT method (Livak and Schmittgen, 2001). -Actin 
did not vary with treatment and there was no difference in -actin expression between control 
and AD cases in any of the brain regions examined (all p>0.06) (Fig. S1A). For details on 
housekeeping gene selection, please refer to the Supplemental Results. 
A42 preparation 
Section Editor: Cellular and Molecular Neuroscience: L. Kaczmarek 
 9
A42 monomers, oligomers, and fibrils were prepared using a modified protocol from Ryan et 
al. (Ryan et al., 2010). Lyophilized A42 peptides were reconstituted in DMSO to a working 
concentration of 1 mM. For experiments, 1 M was used as the final concentration. The 
volume required for each experiment was aliquoted for preparation. For monomers, aliquots 
were sonicated for 10 min and briefly vortexed. For oligomer preparations, after sonication, 
monomers were diluted 1:10 using PBS+0.05% SDS, vortexed for 30 seconds, and incubated 
at 4C for 40 h. For fibril preparations, after sonication, monomers were diluted 1:10 using 
PBS, vortexed for 30 seconds, and incubated at 37C for 40 h.
Atomic Force Microscopy (AFM) 
A42 samples (20 l) prepared as described above were pipetted onto the surface of freshly 
cleaved 1 x 1 cm mica. Samples were incubated on the mica surface for 30 min to allow for 
sufficient adsorption of the A42  samples and then washed by exchanging the sample 
solution (six times) with nanopure water. The A42-coated mica surface was then air dried 
and mounted on the AFM sample stage and static mode force measurements were performed 
using an Asylum Research MFP-3D AFM (Santa Barbara, CA) as previously described 
(Higgins et al., 2006). Images were captured using the Asylum Research AFM IGOR Pro 
software (Wavemetrics, Lake Oswego, OR). 
 
Immunofluorescence staining and fluorescence microscopy 
SHSY5Y cells were seeded in 24-well plates containing sterile 12 × 12 mm glass coverslips 
(density of: 6×104) and differentiated for 9 days as described above. Cells were transfected 
with overexpression plasmids [pcDNA3.1-TrkB-Shc-myc and pcDNA3.1-TrkB-TK+-EGFP 
(constructed and validated by GeneArt)] (100 ng/well) for 24 h using Lipofectamine 2000 (1 
l/well) and washed twice with PBS and fixed with 3% (v/v) formaldehyde/PBS for 15 min 
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at room temperature. After washing with PBS (3×5 min), cells were permeabilised with 0.1% 
(v/v) Triton X-100 in PBS (5 min). After washing with PBS (3×5 min), cells were incubated 
with 10% (v/v) FBS in PBS for 1 h at room temperature. Cells on the coverslips were then 
incubated with primary antibody against myc (Invitrogen) 2 g diluted in 10% (v/v) FBS in 
PBS plus 0.1% (w/v) saponin for 16 h at 4 °C. After washing with 10% (v/v) FBS in PBS 
(3×5 min), cells were incubated with 5 g/ml of Alexa Fluor-594 conjugated mouse 
secondary antibody (Molecular Probes) for 1 h at room temperature. Cells were washed with 
10% (v/v) FBS in PBS (3×10 min). Coverslips were then mounted on glass slides using 
ProLong® Gold antifade reagent with DAPI (Molecular probes). Images were obtained using 
a Nikon ECLIPSE RE2000-E micorscope (Nikon, Japan).
Western blotting 
Tissues (10mg) and cells were harvested for total protein using homogenization buffer 
(human tissue) (Wong et al., 2009) or RIPA buffer (cells) supplemented with protease 
inhibitors (2 mM AEBSF, 0.015 mM aprotinin, 0.038 mM leupeptin, 0.030 mM pepstatin A, 
0.028 mM E-64, 0.08 mM bestatin) (Sigma) and phosphatase inhibitors (Pierce). Protein 
concentrations were determined by the bicinchoninic acid method. Samples (including A 
preparations) were mixed with 5 × SDS loading buffer (containing -mercaptoethanol), 
boiled at 95ºC for 5 min, and separated on 10% or 13% SDS-PAGE gels (13% was used for 
A preparations). Proteins were transferred onto nitrocellulose membranes and blocked 
using 5% (w/v) non-fat milk, 0.1% (v/v) Tween-20 in TBS (TBST) at room temperature for 1 
h. For membranes containing A samples, membranes were boiled in PBS for 5 min prior 
to blocking to expose epitopes in oligomers and fibrils (Takahashi et al., 2004). Membranes 
were incubated with primary antibodies: WO2 (1:500 dilution), which recognizes the A 
peptide; TrkB (1:3000) (BD Biosciences); phospho-TrkB (1:5000) (Epitomics); AKT1 
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(1:5000), phospho-AKT1 (1:5000), ERK1/2 (1:20000), phospho-ERK1/2 (1:20000) (Cell 
Signaling), myc (1:5000) (Invitrogen), and -actin (1:10000) (Sigma). Membranes were 
washed 3 x 10 min with TBST and incubated with mouse peroxidase-conjugated affinity 
purified secondary antibody for 1 h (Dako). After further washing, bound antibodies were 
incubated with enhanced chemiluminescence reagent (Millipore) and visualized by 
autoradiography. Bands were quantitated by densitometry using Image J (version 1.37v) 
(National Institutes of Health USA). The brightness/contrast of images was adjusted using 
Adobe Photoshop CS (version 8). 
 
Statistical analysis 
All cell culture experiments were from 3 replicate cultures representative of 3-6 independent 
experiments. Data are presented as mean + standard error of the mean (SEM). Outliers were 
determined and removed from subsequent analyses using the Grubb’s test or if data points 
were greater or less than two standard deviations from the mean (qPCR: Hippocampus: 
TrkB-Shc: one control and one AD case removed; TrkB-TK-: one control and one AD case 
removed; TrkB-TK+: one control removed; Temporal cortex: TrkB-Shc: one AD case 
removed; TrkB-TK-: one control removed; TrkB-TK+: one control removed; Occipital 
cortex: TrkB-Shc: one AD case removed; TrkB-TK-: one AD case removed; TrkB-TK+: one 
AD removed; Cerebellum: TrkB-Shc: one control and two AD cases removed; TrkB-TK-: 
one control removed; Protein: Hippocampus: truncated TrkB: one control removed; Temporal 
cortex: full-length TrkB: one AD case removed; Occipital cortex: full-length TrkB: one AD 
case removed). Statistical analyses were conducted using STATISTICA 7 (StatSoft Inc., 
2000, STATISTICA for Windows). Tests for normality were conducted. For normally 
distributed data, two-tailed unpaired t-tests were conducted to assess significance in gene 
expression changes. For data with non-normal distribution, the Mann Whitney U test was 
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conducted. A one-way analysis of variance (ANOVA) was conducted to assess significance 
in gene expression changes when incremental treatment concentrations were used. ANOVAs 
were followed up with the Fischer LSD post-hoc analysis to assess the significance between 
treatment groups. Pearson’s Product Moment correlations were conducted to determine if any 
relationship existed between TrkB alternative transcript expression and glial fibrillary acidic 
protein (GFAP) mRNA expression. A p-value less than 0.05 (two-tailed) was considered 
statistically significant. 

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Results
TrkB-Shc transcript levels are increased in the hippocampus of AD brains 
We found highly significant increases in TrkB-Shc mRNA levels in the hippocampus of AD 
brains compared to controls (t=-4.03, df=8, p=0.004) (Fig. 2A). A trend towards increased 
TrkB-TK- mRNA levels was observed in the AD hippocampus compared to controls (t=-
2.10, df=8, p=0.07). No significant change in hippocampal TrkB-TK+ mRNA levels could be 
detected between control and AD cases (t=-1.26, df=9, p=0.24).   
To determine whether the increase observed in TrkB-Shc mRNA levels are related to 
the location and severity of tissue pathology, we assessed whether changes in TrkB-Shc 
mRNA expression are altered in the temporal cortex (a region affected after the 
hippocampus) as well as the occipital cortex and cerebellum (two regions less affected in 
AD). Interestingly, we found no significant change in TrkB-Shc mRNA levels in any of the 
three brain regions examined between control and AD cases (all p>0.17) (Fig. 2B-D). 
Moreover, no significant differences were observed in TrkB-TK- (all p>0.16) or TrkB-TK+ 
(all p>0.20) mRNA levels between control and AD cases.   
 
TrkB protein expression in AD
TrkB immunoreactive bands migrating at ~140kDa (corresponding to full-length TrkB) and 
~90kDa (corresponding to truncated TrkB) were detected in all control and AD samples in all 
four brain regions examined (Fig. 3A). The ~90kDa band appeared large and diffuse in all 
samples from all four brain regions. This is likely because the TrkB-TK- and TrkB-Shc 
isoforms are similar in size and both migrate at ~90kDa. We observed significant increases in 
the ~90kDa TrkB protein in the hippocampus (t=-2.67, df=9, p=0.03) and temporal cortex 
(t=-3.60, df=15, p=0.003) of AD brains compared to controls (Fig. 3B and C). No significant 
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difference in expression of the ~90kDa protein was observed between AD and controls in the 
occipital cortex (U=16, Z=1.68, p=0.09) and cerebellum (t=-1.61, df=10, p=0.14) (Fig. 3D 
and E).  
 Interestingly, expression of the ~140kDa band corresponding to the TrkB-TK+ 
protein was significantly increased in the hippocampus of AD brains compared to controls 
(U=4, Z=-2.24, p=0.02) (Fig. 3B). No significant differences were observed in expression of 
the ~140kDa protein in the temporal cortex, occipital cortex, and cerebellum between AD 
and control brains (Fig. 3C-E) (all p>0.09). 
 
GFAP mRNA levels in AD 
Elevations in TrkB-TK- mRNA and truncated TrkB protein levels in AD have previously 
been associated with increased astrocyte numbers in the diseased state (Duguid et al., 1989, 
Muramori et al., 1998). To determine if the increases in TrkB-TK- mRNA (trend only) and 
truncated TrkB protein levels we observed are associated with changes in astrocytes in AD, 
we measured GFAP mRNA levels in the same brain regions where TrkB alternative 
transcript levels were assessed. We found elevated levels of GFAP mRNA in the 
hippocampus (U=5, Z=-2.08, p=0.04), temporal cortex (t=-3.47, df=15, p=0.003), and 
occipital cortex (U=9, Z=-2.60, p=0.009) of AD brains compared to controls (Fig. S2A-C). 
No significant change in GFAP transcript levels was observed in the AD cerebellum (t=-0.35, 
df=8, p=0.73) (Fig. S2D). When we examined whether changes in TrkB-TK- mRNA and 
truncated protein levels were correlated with changes in GFAP mRNA levels, we found that 
TrkB-TK- mRNA levels did not correlate with changes in GFAP mRNA levels in any brain 
region examined. Interestingly, we found significant positive correlations between truncated 
TrkB protein expression and GFAP mRNA levels in the hippocampus (r=0.89, p=0.0003) and 
temporal cortex (r=0.51, p=0.04) but no association between truncated TrkB protein and 
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GFAP mRNA levels in the occipital cortex or cerebellum (all p>0.27). GFAP mRNA levels 
did not correlate with TrkB-Shc, with TrkB-TK+ mRNA levels, or with full-length TrkB 
protein expression in any brain region examined.  
 
A42
We prepared different structural forms of A using a modified protocol from Ryan et al. 
(Ryan et al., 2010). The presence of A monomers, oligomers, and fibrils were confirmed 
by western blotting (using WO2 antibody which recognizes the A peptide) and found to be 
consistent with Apreparations previously reported by us and by others (Garzon and 
Fahnestock, 2007, Kagedal et al., 2010, Ryan et al., 2010) (Fig. 4A). The monomeric A 
preparation (lane 1) contained mostly monomers (~4 kDa) but it also contained small 
oligomers (12-22 kDa). We did not detect any large oligomers or fibrils. The oligomeric 
Apreparation (lane 2) contained monomers, small and large oligomers (40-70 kDa). The 
fibrillar A preparation (lane 3) contained monomers, small oligomers, some large 
oligomers, and fibrils (>250 kDa). 
 To extend our characterization of the A preparations utilized in this study, in 
addition to western blotting, we also visualized the three different Apreparations using 
AFM (Fig. 4B). The monomer preparation contained monomers and small aggregates of 
A. These are likely to correspond to the small oligomers observed in western blot analysis 
(Fig. 4A lane 1). Also similar to our findings by western blotting, we observed varying sizes 
of A oligomers and fibrils in their respective preparations by AFM. In the oligomer 
preparation, we found evidence of some oligomers aggregating into fibrils (Fig. 4B and S3A). 
However, it was in the fibril preparation that most fibrillar A species were observed (Fig. 
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4B and S3B), including protofibrils which can reach up to ~100 nm in length (Arimon et al., 
2005) as indicated by the black arrows in Figure S3B.   
Fibrillar A42 increases TrkB-Shc transcript levels in the differentiated SHSY5Y 
neuronal cell-line 
The increase in TrkB-Shc mRNA levels in the AD hippocampus but not in other brain 
regions examined suggests that factors specific to severe AD pathology may be modulating 
its expression. Thus, we determined whether TrkB alternative transcript expression in 
neuronal cell-lines can be modulated by different species of A. We found a modest but 
significant increase in TrkB-Shc mRNA levels (t=-2.33, df=15, p=0.03) in differentiated 
SHSY5Y neuronal cells treated with preparations of A containing fibrils but not with 
preparations containing monomers or oligomers(all p>0.36) (Fig. 5). No significant changes 
in TrkB-TK- (all p>0.07) and TrkB-TK+ (all p>0.17) mRNA levels were observed in any of 
the treatment conditions. 
 
TrkB-Shc co-localizes with TrkB-TK+ 
TrkB-Shc has previously been shown to co-localize with TrkB-TK+ in non-neuronal cells 
(Stoilov et al., 2002). To determine whether TrkB-Shc can co-colocalize with TrkB-TK+ in 
neuronal cells, we co-overexpressed TrkB-Shc and GFP-tagged TrkB-TK+ in differentiated 
SHSY5Y cells. We observed co-localisation between TrkB-TK+ and TrkB-Shc (Fig. 6). Both 
TrkB-Shc and TrkB-TK+ showed cytoplasmic and plasma membrane localisation (Fig. 6A, 
B, and D). Expression of both isoforms could also be observed in neurites. TrkB-TK+ was 
found to localise mostly around the soma, whereas TrkB-Shc was observed to distribute into 
more distal regions of neurites. Interestingly, TrkB-TK+ and to a lesser extent, TrkB-Shc, 
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were found to be highly concentrated in the endoplasmic reticulum. No expression of either 
isoform could be detected in the nucleus (Fig. 6A-D).    
 
Increased TrkB-Shc expression dampens BDNF-stimulated-TrkB-TK+ mediated 
second messenger signalling via the MEK pathway 
We next determined whether increased TrkB-Shc protein expression impacts on 
BDNF/TrkB-TK+ signaling in a neuronal setting. Differentiated SHSY5Y cells were 
transiently transfected with either empty vector or myc-tagged TrkB-Shc plasmids and 
treated with incremental concentrations of BDNF. In cells transfected with the empty vector 
plasmid, treatment with exogenous BDNF increased TrkB, ERK1/2, and AKT 
phosphorylation in a concentration dependent manner (all F>3.02, df=3, p<0.02) (Fig. 7A). In 
cells transfected with TrkB-Shc-myc, BDNF treatment also increased TrkB, ERK1/2, and 
AKT phosphorylation (all F>4.14, df=3, p<0.03) (Fig. 7A). No change was observed in total 
protein levels in the empty vector and TrkB-Shc transfected cells with or without BDNF 
treatment. 
 When we examined the ratio of phosphorylated to total (phosphorylated + non-
phosphorylated) levels of TrkB, ERK1/2, and AKT as a measure of activity, we found that 
overexpression of TrkB-Shc in differentiated SHSY5Y cells diminished the BDNF-
stimulated increase in pERK1:ERK1 expression ratio (comparing empty vector to TrkB-Shc 
transfected at 5ng BDNF treatment: t=2.79, df=6, p=0.03; comparing empty vector to TrkB-
Shc transfected at 15ng BDNF treatment: t=2.47, df=6, p=0.049) and abolished the BDNF-
stimulated increase in pERK2:ERK2 expression ratio compared to cells transfected with the 
empty vector (empty vector: F=3.66, df=3, p=0.04 compared to TrkB-Shc: F=0.08, df=3, 
p=0.97) (Fig. 7B).  TrkB-Shc overexpression had no significant impact on BDNF-stimulated 
pAKT:AKT expression ratio compared to empty vector transfected cells. Interestingly, in 
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both empty vector and TrkB-Shc transfected cells, treatment of cells with 25ng of BDNF had 
little effect on pAKT:AKT, pERK1:ERK1, and pERK2:ERK2 expression ratios and levels 
appeared similar to the vehicle treatment condition. This finding suggests that our 
experimental system was likely to have been saturated at 25ng BDNF. This is likely as 
treatment with 25ng BDNF had a more potent effect at increasing the pTrkB:TrkB-TK+ 
expression ratio than in the empty vector (t=-3.03, df=6, p=0.02).  
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Discussion 
In this study, we report several novel findings: First, we found elevated levels of the neuron-
specific truncated TrkB alternative transcript, TrkB-Shc in the hippocampus but not in the 
temporal cortex, occipital cortex, and cerebellum of AD brains. Second, we found that 
exposure of differentiated SHSY5Y neuronal cell-lines to A preparations containing fibrils 
increased TrkB-Shc transcript levels. Finally, increasing TrkB-Shc protein expression in 
differentiated SHSY5Y cells attenuated BDNF-stimulated-TrkB-TK+ mediated second 
messenger signaling via the MEK pathway. 
 
TrkB-Shc and AD 
To date, TrkB-Shc expression in AD brain tissues has yet to be described. Considering that 
TrkB-Shc expression is neuron-specific (Stoilov et al., 2002), it is surprising that this gap in 
the knowledgebase exists. Here, we show that TrkB-Shc transcripts are elevated in the AD 
hippocampus, but not in the temporal cortex, occipital cortex, or cerebellum; suggesting that 
increases in this TrkB alternative splice transcript is occurring in brain regions that are most 
severely affected in the diseased state and that the observed increase may likely be influenced 
by the neuronal cell population. In support of this, we found that TrkB-Shc mRNA levels in 
differentiated neuronal cell-lines can be increased by exposure to preparations of A 
containing fibrils. Interestingly, Apreparations that did not contain fibrillar A species 
had no significant effect on TrkB-Shc transcript levels. 
At present, it is widely accepted that soluble oligomers are the more neurotoxic of the 
A species, however, evidence also indicates that the neurotoxicity of A requires its 
aggregation in the fibrillar form, particularly in the form of protofibrils (Walsh et al., 1999, 
Serpell, 2000). By AFM, we were able to detect various sizes of fibrils in the fibril A 
preparations, including protofibrils which can be ~100 nm in length. Our images of the fibril 
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preparations are very similar to those reported by Arimon et al. (2005). Here, the authors 
found that protofibrils co-exist with larger fibrils and are able to incorporate into larger 
fibrillar structures. In our preparations, we observed similar finidings. In the oligomer 
preparations, while we observed evidence of some oligomers aggregating into fibrils, the 
predominant form of A were globular oligomers of various sizes. Considering that A 
fibrils are formed in the advanced stages of AD (Hoozemans et al., 2006), that the 
hippocampus is the most impacted brain region, and that the CA1 subregion (the 
hippocampal region assessed in this study) is the most severely impacted subregion of the 
hippocampus in AD, altogether, our findings suggest that the selective increase in the TrkB-
Shc alternative splice transcript in the AD hippocampus may be specific to severe, late stage 
pathology.  
In the AD hippocampus, we found a trend towards an increase in TrkB-TK- mRNA 
levels but a significant elevation in truncated TrkB protein. Both TrkB-TK- and TrkB-Shc are 
predicted to migrate at similar molecular weights by denaturing SDS-PAGE, thus the 
increase in truncated TrkB protein is likely to reflect an increase in both TrkB-TK- and TrkB-
Shc protein in the total hippocampal brain homogenate. While an increase in TrkB-TK- 
mRNA levels and truncated TrkB protein are consistent with previous findings (Connor et al., 
1996, Ferrer et al., 1999), it is in contrast to the lack of change we observed in differentiated 
SHSY5Y cells exposed to A. TrkB-TK- is primarily expressed by astrocytes and previous 
studies have demonstrated that TrkB-TK- signaling via Rho-GTPase is critical in regulating 
astrocyte morphology (Ohira et al., 2005a). Considering that astrocytes become activated 
when exposed to A, the increase in TrkB-TK- in the AD hippocampus may be more 
reflective of increases in astrocytic TrkB-TK- expression as opposed to neuronal TrkB-TK- 
expression. This is likely as elevations in TrkB-TK- mRNA in AD have previously been 
found to be associated with reactive glia around senile plaques (Ferrer et al., 1999). 
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Moreover, when we surveyed GFAP mRNA levels in the hippocampus, temporal cortex, 
occipital cortex, and cerebellum, we found statistically significant elevations in all brain 
regions except for the cerebellum (a region relatively spared in AD). 
Interestingly, while we found no significant changes in TrkB-TK+ mRNA levels in 
any of the four brain regions tested in AD compared to controls, we did find a significant 
increase in full-length TrkB protein in the hippocampus. This is consistent with previous 
findings which showed that both truncated and full-length TrkB immunoreactivity in the CA1 
subregion of the hippocampus are elevated in AD compared to controls (Connor et al., 1996). 
Moreover, both truncated and full-length TrkB immunoreactivity detected by Connor et al. 
(1996) was found to localise to glial cells in association with senile plaques. Considering that 
astrocytes are also able to express TrkB-TK+ mRNA and full-length TrkB protein, our 
finding of elevated full-length TrkB protein in the AD hippocampus suggests that the 
increase is likely to be contributed by astrocytes. 
In addition to the hippocampus, we also found a significant increase in truncated TrkB 
protein in the temporal cortex but not in the occipital cortex and cerebellum, consistent with 
previous findings (Allen et al., 1999). The occipital cortex is affected less severely in AD and 
the cerebellum is relatively spared. If we take into consideration our finding of increased full-
length TrkB protein in the AD hippocampus, and findings of elevated GFAP mRNA levels in 
the hippocampus and temporal and occipital cortices, altogether, our findings may also be 
reflective of the progression of AD brain pathology ie. where pathology is most severe in the 
hippocampus>temporal cortex>occipital cortex>cerebellum.  
    
Increased TrkB-Shc in AD: a negative regulator of BDNF/TrkB-TK+ signaling in AD? 
The cellular response to BDNF is mediated by the full-length TrkB receptor, TrkB-TK+, and 
this can be modulated depending upon the relative ratios of the full-length TrkB to truncated 
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TrkB receptors (Eide et al., 1996). Changes in the relative levels of truncated TrkB receptors 
have been demonstrated to have a significant impact on neuronal BDNF availability and 
signaling. Co-expression of TrkB-TK- and TrkB-Shc in vitro have been found to have a 
dominant negative effect on TrkB-TK+ activity (Biffo et al., 1995, Eide et al., 1996, Ninkina 
et al., 1996, Stoilov et al., 2002). In accordance with these findings, we showed that TrkB-
Shc can have a negative impact on human neuronal BDNF/TrkB-TK+ second messenger 
signaling via the MEK pathway where BDNF/TrkB-TK+ mediated phosphoryation of both 
ERK1 and ERK2 were reduced when exogenous TrkB-Shc was overexpressed. In contrast, 
little change was obseved in BDNF-stimulated phosphorylation of TrkB and AKT when 
TrkB-Shc was overexpressed. Unlike TrkB-TK+ signaling via the MEK pathway, which 
requires Shc adaptor proteins to bind to phosphorylated tyrosine residues on TrkB-TK+, 
signaling via AKT can also mediated via IRS1/2 (Yamada et al., 1997). Thus, the lack of 
change in AKT phosphorylation upon TrkB-Shc overexpression may have resulted from 
alternative pathways being utilized upon BDNF stimulation. 
 
Increased TrkB-Shc in AD: a compensatory response to promote cell survival in AD?  
While there is evidence to support the notion that increased TrkB-Shc will negatively impact 
neuronal BDNF signaling (Biffo et al., 1995, Eide et al., 1996, Ninkina et al., 1996, Stoilov et 
al., 2002), recent evidence suggests that TrkB-Shc may play a protective role in AD by 
promoting cell survival. It was recently demonstrated that overexpression of TrkB-Shc can 
modulate APP metabolism by decreasing APP intracellular domain (ICD)-mediated 
transcription (AICD) (Ansaloni et al., 2011). The AICD is a positive transcriptional regulator 
of apoptosis and is suggested to further accelerate neurodegeneration by contributing to the 
toxic effect of A42 aggregates in vivo.  
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 In our current study, we found that overexpression of TrkB-Shc in differentiated 
SHSY5Y cells could blunt BDNF/TrkB-TK+ stimulated MEK pathway signaling by 
attenuating pERK1/2:ERK1/2 ratios (a measure of ERK1/2 activity) but with little effect on 
pTrkB:TrkB-TK+ and pAKT:AKT ratios. In AD, MEK signaling and ERK1/2 
phosphorylation is increased in vulnerable neurons, moreover, elevated MEK pathway 
activity is implicated in the abnormal phosphorylation of tau and neurofilament proteins 
(Perry et al., 1999). Considering that BDNF/TrkB-TK+ mediated neuronal survival is more 
dependent upon AKT signaling than MEK signaling (Atwal et al., 2000), our finding that 
elevated levels of TrkB-Shc in a neuronal setting can attenuate ERK1/2 phosphorylation 
following BDNF stimulation (but have no significant effect on phosphorylated AKT and 
TrkB at non-saturating levels) suggests that the increase in TrkB-Shc transcripts in the AD 
hippocampus and when cells are treated with fibrillar A, may function as  a compensatory 
mechanism in neurons in AD to promote survival. Further work is required to determine how 
TrkB-Shc is functioning in neurons in AD and whether changes in their expression at 
different stages of the disease process, in response to A, or in response to other 
amyloidogenic factors may be protective or deleterious. 
 
Conclusions
In this study, we demonstrated a novel increase in TrkB-Shc transcript levels in the AD 
hippocampus and present evidence to suggest that the increased expression of this TrkB 
alternative splice transcript may be induced by exposure of neuronal cells to fibrillar A42 
species. Our finding that TrkB-Shc can preferentially dampen BDNF-stimulated TrkB-TK+ 
second messenger signaling via the MEK pathway but not the AKT pathway provides 
compelling evidence to suggest that increases in TrkB-Shc may have a protective role in 
promoting cell survival pathways but without further activating an already overactive MEK 
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signaling pathway in AD. Further work aimed at identifying how splicing of the TrkB 
alternative transcripts in neurons is modulated in AD would be an important step in 
understanding how TrkB-Shc expression is modulated in AD. 
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Figure Legends 
Table 1. Cohort Demographics 
Table 2. Primer Sequences 
Fig. 1. TrkB gene and protein structure 
In the upper panel, exons are represented by numbered rectangles, lines joining exons depict 
exon splicing. Colored exons correspond to protein domains in lower panel. White exons 
represent non-coding sequences. Nomenclature and gene organization derived from Luberg et 
al. (Luberg et al., 2010) and Wong et al. (Wong et al., 2011).    
Fig. 2. TrkB alternative transcript expression in AD 
Expression of TrkB alternative transcripts in the (A) hippocampus, (B) temporal cortex, (C) 
occipital cortex, and (D) cerebellum of control (white) and AD (black) brains were measured 
by qPCR. **=p=0.004; #=p=0.07. 
Fig. 3. TrkB protein expression in AD 
Expression of truncated (90 kDa) and full-length (140 kDa) TrkB protein in the (A) 
hippocampus, (B) temporal cortex, (C) occipital cortex, and (D) cerebellum of control (white) 
and AD (black) brains were measured by western blotting. **=p=0.003; *=p=0.02 (140 kDa 
band) and p=0.03 (90 kDa band). 
Fig. 4. A42 preparations  
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(A) Lane 1 is predominantly monomers and also includes some small oligomers. Lane 2 
consists of large oligomers (40-70 kDa) which are absent in lanes 1. Lane 3 consists of fibrils 
(>250 kDa) which are absent in lanes 1 and 2. (B) Atomic force microscopy images of the 
monomer (lane 1), oligomer (lane 2), and fibril (lane 3) preparations from panel (A). (i) The 
monomer preparations contained monomers. Aggregation of monomers also can be seen. (ii) 
The oligomer preparation contained monomers and oligomers of various sizes. Aggregation 
of oligomers into fibrils is evident. (iii) The fibril preparation contained A fibrils of 
various sizes. Scale represents 1 m. 
Fig. 5. Effect of different structural forms of A42 on TrkB alternative transcript 
expression in the differentiated SHSY5Y neuronal cell-line 
SHSY5Y cells were differentiated for 9 days and incubated in the absence (white bars) or 
presence of A42 monomers (AM) (grey bars), oligomers (AO) (black bars), and fibrils 
(AF) (hatched bars) for 6 h and harvested. Expression of TrkB alternative transcripts were 
then measured by qPCR. Data is expressed as mean + SEM relative to the control condition 
which was set to 1. *=p=0.03. Representative of n=6 separate experiments.  
Fig. 6. Localization of TrkB-TK+ and TrkB-Shc in differentiated SHSY5Y neuronal 
cell-line
Differentiated SHSY5Y (A-D) cells were transfected with TrkB-TK+-EGFP or TrkB-Shc-
myc for 24 h.  Cells were fixed and immunoprobed with myc antibody for TrkB-Shc protein 
expression (green for TrkB-TK+EGFP and red for myc tagged TrkB-Shc) and stained with 
DAPI (blue).  Note: no colocalization with DAPI (blue) was observed in either the green 
(TrkB-TK+-EGFP) or red (myc-tagged TrkB-Shc) channels. Representative of n=3 separate 
experiments. 
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Fig. 7. Effect of TrkB-Shc overexpression on BDNF-stimulated TrkB-K+ second 
messenger signaling in differentiated SHSY5Y neuronal cell-line 
Differentiated SHSY5Y cells were transfected with either empty vector (EV; blue) or TrkB-
Shc-myc (pink) for 24 h and treated with increasing concentrations of BDNF for 15 minutes 
and harvested.  Proteins were separated by SDS-PAGE and immunoprobed.  (A) 
Representative western blot images from n=4 independent experiments.   (B) Bands were 
quantitated by densitometry and presented as protein expression ratios of phosphorylated 
protein to non-phosphorylated protein (pTrkB-TK+:TRkB-TK+; pAKT:AKT; pERK1:ERK1; 
pERK2:ERK2) -/+ SEM. *=p=0.02 for pTrkB:TrkB-TK+ at 25ng, p=0.03 for pERK1:ERK1 
at 5ng BDNF and p=0.049 for pERK1:ERK1 at 15ng BDNF. Representative of n=4 separate 
experiments. 
Fig. S1. -Actin mRNA expression in AD 
(A) CT values of -actin from qPCR of the hippocampus (HP), temporal cortex (TC), 
occipital cortex (OC), and cerebellum (CB) of control (white) and AD (black) brains. (B) -
Actin mRNA levels was normalized to the geometric mean calculated from -actin, 
cyclophillin, and porphobilinogen deaminase to show that -actin mRNA levels is not 
affected by diagnosis.  
Fig. S2. GFAP mRNA expression in AD 
Expression of GFAP mRNA in the (A) hippocampus (HP), (B) temporal cortex (TC), (C) 
occipital cortex (OC), and (D) cerebellum (CB) of control (white) and AD (black) brains was 
measured by qPCR.  **=p=0.003 (temporal cortex) and p=0.009 (occipital cortex); *=p=0.04 
(hippocampus). 
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Fig. S3. Atomic force microscopy of A42 species 
Magnified AFM images of the (A) oligomer and (B) fibril preparations from Fig. 4. Scale 
represents 0.5 m for (A) and 0.2 m for (B). Black arrows in (B) indicate protofibrils which 
can reach up to ~100 nm in length.
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Table 1. Cohort Demographics
Diagnosis Regions Gender Age (years) PMI (h)
Control hippocampus, cerebellum Male 82 23.5
Control hippocampus, cerebellum Female 78 11
Control hippocampus, cerebellum Male 69 13.5
Control hippocampus, cerebellum Female 93 21
Control hippocampus, cerebellum Female 85 23
Control hippocampus, cerebellum Male 79 8
Control occipital, temporal Female 61 26
Control occipital, temporal Male 69 48
Control occipital, temporal Female 73 44
Control occipital, temporal Male 75 60
Control occipital, temporal Female 77 48
Control occipital, temporal Female 83 28
Control occipital, temporal Female 91 40
Control occipital, temporal Female 93 17
AD hippocampus, cerebellum Male 83 27
AD hippocampus, cerebellum Female 84 9
AD hippocampus, cerebellum Female 83 23
AD hippocampus, cerebellum Male 73 20
AD hippocampus, cerebellum Female 83 7
AD hippocampus, cerebellum Male 69 15
AD occipital, temporal Female 65 36
AD occipital, temporal Male 67 38
AD occipital, temporal Female 68 36
AD occipital, temporal Male 71 36
AD occipital, temporal Female 75 76
AD occipital, temporal Female 78 24
AD occipital, temporal Female 78 43
AD occipital, temporal Female 80 48
AD occipital, temporal Male 83 30
AD occipital, temporal Male 90 9
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A.TrkBTK+ B.TrkBShc
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